AIM ImmunoTech Inc. experienced a dramatic surge in its stock price on Monday, with shares more than doubling in heavy trading volume following an update from its pancreatic cancer trial. The company announced that the final planned subject in its Phase 2 DURIPANC study had met enrollment criteria, pushing the trial ahead of its earlier July target.
The stock reached 92.79 cents, up 52.01 cents on the session, with volume exceeding 312 million shares. The intraday range was notably wide, from 42.33 cents to $1.215, reflecting significant volatility typical of small-cap biotech stocks.
The DURIPANC trial is testing AIM's lead drug, Ampligen (rintatolimod), in combination with AstraZeneca's Imfinzi (durvalumab), an immune checkpoint inhibitor. The study is focused on patients with metastatic pancreatic cancer whose disease has stabilized after standard FOLFIRINOX chemotherapy. The primary endpoint is clinical benefit rate, which measures the proportion of patients achieving stable disease, partial response, or complete response.
Chief Executive Thomas K. Equels described the enrollment milestone as an “important execution milestone” for the program. The company now expects the last patient to receive treatment in mid-June, assuming no pre-treatment disqualifications. An interim report is anticipated within the next two to three weeks, with the main efficacy readout scheduled for December 2026.
The positive news came against a backdrop of a generally soft biotech sector. The SPDR S&P Biotech ETF (XBI) was down approximately 1.6% on the day, while the broader S&P 500 ETF (SPY) edged up 0.4%. This divergence underscores the stock-specific nature of AIM's rally.
Pancreatic cancer has become a particularly active area for investors following recent positive data from Revolution Medicines, whose drug daraxonrasib nearly doubled median overall survival versus chemotherapy in a Phase 3 study of previously treated metastatic disease. Brian M. Wolpin of Dana-Farber, the principal investigator for the DURIPANC trial, emphasized that “new treatment options are urgently needed” for these patients. Additionally, Oncolytics Biotech announced plans for further preclinical work on pelareorep with RAS-targeted approaches, including in pancreatic ductal adenocarcinoma models, keeping AIM in a competitive and fast-moving niche despite its earlier stage of development.
Investors should also consider the company's financial position. In a May 20 securities filing, AIM disclosed an agreement to sell 7.5 million shares at 32.5 cents each, along with warrants to purchase up to approximately 15.0 million additional shares at the same exercise price. The registered offering was expected to raise about $2.4 million before expenses, introducing potential dilution risk for existing shareholders.
While the accelerated enrollment is a positive sign, it does not guarantee trial success. The last subject must still clear pre-treatment conditions, and the key efficacy readout remains months away. Further financing or warrant exercises could dilute holders, and a weak interim update could leave the stock vulnerable after Monday’s sharp rally. For now, the market is pricing in the value of time gained, but the ultimate test will be whether Ampligen can generate data strong enough to support a planned Phase 3 push.
